Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: A pilot randomized controlled study

Although hepatitis B surface antigen (HBsAg) removal is considered the goal of chronic hepatitis B treatment, it can rarely be achieved with nucleos(t)ide analogues (NAs). It has been reported that tenofovir disoproxil fumarate (TDF) is superior in reducing HBsAg compared with entecavir (ETV) in tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Jun, Akahane, Takehiro, Kobayashi, Tomoo, Obara, Noriyuki, Umetsu, Teruyuki, Kakazu, Eiji, Ninomiya, Masashi, Iwata, Tomoaki, Sano, Akitoshi, Tsuruoka, Mio, Sato, Kosuke, Masamune, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739848/
https://www.ncbi.nlm.nih.gov/pubmed/33335726
http://dx.doi.org/10.3892/br.2020.1396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739848/
https://www.ncbi.nlm.nih.gov/pubmed/33335726
http://dx.doi.org/10.3892/br.2020.1396

Ejemplares similares